Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68 PSMA Ligand for Prostate Cancer Localization
NCT03207139Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Diagnostic sensitivity of the Ga-68 PSMA ligand at 3 years. Started Jun 2017; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03207139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207139.